The aim of the Education Committee (EC) is to coordinate ESOT’s efforts to advance multidisciplinary education for transplant professionals at all career levels and to contribute to their professional development.
The Basic Science Committee promotes scientific issues and transplantation research within ESOT. An active basic science community and an efficient translation of innovation into the clinic are crucial for the future of transplantation medicine.
The European Transplant Allied Healthcare Professionals (ETAHP) reaches out to allied healthcare professionals throughout Europe in order to ensure the best care possible for all transplant patients, with the aim to optimize patient outcomes.
The Young Professionals in Transplantation (YPT) is the Network for Junior Transplant professionals of ESOT, representing all young transplant clinicians and scientists who are beginning a career in transplantation and organ donation.
The mission of ECTORS is to provide a forum for discussing and stimulating novel developments in the fields of cellular therapies in organ transplantation, organ regeneration and generation of new organs from stem cells and biomaterials.
ECTTA is the forum for experience exchange on treatment of patients with end-stage heart and lung failure. Our aim is to improve outcomes for the patients.
EDTCO aims to support health care professionals to provide clinically effective programmes on organ and tissue donation, procurement and transplantation.
EKITA is the Organ Expert Section of ESOT on kidney transplantation in Europe, providing a forum for kidney transplantation professionals to exchange scientific information and views aimed at providing the best service to European patients .
The European Liver and Intestine Transplant Association (ELITA), previously known as the European Liver Transplant Association (ELTA), is a section of ESOT. Its membership represents the expertise on liver and intestinal transplantation in Europe.
ELPAT is a European platform that brings continuity and progress in European research and dialogue on "Ethical, Legal and Psychosocial Aspects of organ Transplantation". ELPAT currently consists of over 160 experts from more than 25 European countries.
EPITA is established to provide a forum for those working in the field of pancreas and islet of Langerhans transplantation or any other alternative form of beta cell replacement in Europe, to exchange scientific information and views related primarily to providing the best service for patients in Europe requiring pancreas or islet transplantation.
VCA has opened a new era in the field of transplantation, reconstructive and restorative surgery. This Section brings together 10 representatives of major European teams at the forefront in this field.
This is the first of two webinars dedicated to presenting and discussing the articles included in the supplement published on Transplant International – Special Issue “Clinical trial design and endpoints in kidney transplantation”. The supplement provides a detailed summary of key aspects of the proposals and recommendations for definitions of endpoints for clinical trials of kidney transplantation.
In the supplement, a panel of European experts redefines the immune risk stratification and endpoints for clinical trials in kidney transplantation. Both the rationale and proposals for established (rejection, graft function) and newer endpoints (including surrogate endpoints and patient-reported outcomes) are presented, as well as the responses from the European Medicines Agency (EMA) on these proposals. This Special Issue will serve as a guide for the design of future clinical trials aiming at improving outcome after kidney transplantation.
Transplant nephrologists/surgeons, HLA specialists, renal/transplant pathologists, clinical trial nurses and clinical trialists, transplant researchers, representatives of patients societies and patients advocates, representatives of pharmaceutical companies, health authorities
18:00 – 18:05: Executive summary – Redefining Risk Stratification and Endpoints for Clinical Trials in Kidney Transplantation: Rationale and Methodology of Proposals Submitted to the EMA by ESOT; Maarten Naesens | Leuven, Belgium
18:05 – 18:15: Alloimmune risk stratification for kidney transplant rejection; Olivier Thaunat | Lyon, France
18:15 – 18:25: Evolution of the Definition of Rejection in Kidney Transplantation and Its Use as an Endpoint in Clinical Trials; Jan Ulrich Becker | Cologne, Germany
18:25 – 18:35: Proposed Definitions of T Cell-mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation; Marion Rabant | Paris, France
18:35 – 18:45: Proposed Definitions of Antibody-Mediated Rejection for Use as a Clinical Trial Endpoint in Kidney Transplantation; Candice Roufosse | London, UK
18:45 – 19:00: Q&A and open discussion
Closing remarks: Maria Irene Bellini | Rome, Italy and Maarten Naesens | Leuven, Belgium
